Possibilities of the biologically active complex of phytopreparations in the correction of menopausal disorders
- Authors: Yashchuk A.G.1, Dautova L.A.1, Shaikhutdinova O.V.2, Muslimova L.R.2, Berg P.A.1, Berg E.A.1, Nasyrova S.F.1, Kizko I.A.3, Nazyrova A.G.3
-
Affiliations:
- Bashkir State Medical University, Ministry of Health of Russia
- City Clinical Hospital No. 5
- Anti-aging Medical Clinic GeN
- Issue: No 6 (2024)
- Pages: 124-132
- Section: Exchange of Experience
- URL: https://journals.eco-vector.com/0300-9092/article/view/634450
- DOI: https://doi.org/10.18565/aig.2024.127
- ID: 634450
Cite item
Open Access
Access granted
Abstract
Objective: To conduct a comparative assessment of the effectiveness of a biologically active complex of phytopreparations and menopausal hormone therapy (MHT) in the treatment of the climacteric syndrome (CS).
Materials and methods: This was a prospective analysis of the effectiveness of using the biologically active complex of phytopreparations NOW Menopause Support 560 mg and MHT in the treatment of CS in women 6 months after receiving therapy. Group 1 included 50 women with CS who received a phytopreparation made on the basis of soy isoflavonoids, cimicifuga rhizome, and red clover isoflavones. Group 2 included 42 patients who received systemic MHT.
Results: According to the Greene Climacteric Scale, the emotional state significantly improved (10.0 (8.0; 14.0) scores) in the group receiving systemic MHT after 6 months from the beginning of therapy, but it was worse than in the other group (p=0.044). The somatic condition effectively improved in the group receiving MHT (3.0 (3.0; 6.0) scores), however it was not different from the condition of women in the group receiving phytopreparations after 6 months of therapy (3.0 (3.0; 6.0) scores), p=0.233. Vasomotor symptom status significantly improved (p<0.001) in both groups after 6 months of treatment. It was assessed as 3.0 (2.0; 5.0) scores in the group of patients after taking MHT and it differed from the group receiving phytopreparations which was 1.0 (1.0; 3.0) scores (p=0.032); it was associated with the presence of milder forms of vasomotor manifestations of CS in the group receiving phytopreparations.
Conclusion: The treatment of CS with phytopreparations and systemic MHT showed high effectiveness. The phytopreparation made on the basis of soy isoflavonoids, cimicifuga rhizome, red clover isoflavone shows positive results in the treatment of the whole spectrum of menopausal disorders, but it can be used with greater benefit for women with moderate severity of symptoms, where the dominant symptoms are somatic and emotional manifestations.
Full Text
About the authors
Alfiya G. Yashchuk
Bashkir State Medical University, Ministry of Health of Russia
Email: alfiya_galimovna@mail.ru
ORCID iD: 0000-0003-2645-1662
Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology No. 2
Russian Federation, UfaLiliana A. Dautova
Bashkir State Medical University, Ministry of Health of Russia
Email: lili.d5@yandex.ru
ORCID iD: 0000-0002-8281-5515
PhD, Associate Professor at the Department of Obstetrics and Gynecology No. 2
Russian Federation, UfaOlga V. Shaikhutdinova
City Clinical Hospital No. 5
Email: p.a.berg@mail.ru
ORCID iD: 0009-0009-2721-4440
obstetrician-gynecologist, Chief Physician
Russian Federation, UfaLeisan R. Muslimova
City Clinical Hospital No. 5
Email: p.a.berg@mail.ru
ORCID iD: 0009-0009-2782-541X
Head of Antenatal Clinic
Russian Federation, UfaPolina A. Berg
Bashkir State Medical University, Ministry of Health of Russia
Author for correspondence.
Email: p.a.berg@mail.ru
ORCID iD: 0000-0001-5266-0412
Teaching Assistant, Department of Obstetrics and Gynecology No. 2
Russian Federation, UfaEdvard A. Berg
Bashkir State Medical University, Ministry of Health of Russia
Email: nucleardeer@gmail.com
ORCID iD: 0000-0002-2028-7796
PhD, Associate Professor at the Department of Obstetrics and Gynecology No. 2
Russian Federation, UfaSvetlana F. Nasyrova
Bashkir State Medical University, Ministry of Health of Russia
Email: ufa863@mail.ru
ORCID iD: 0000-0002-2313-7232
PhD, Associate Professor at the Department of Obstetrics and Gynecology No. 2
Russian Federation, UfaIrina A. Kizko
Anti-aging Medical Clinic GeN
Email: nucleardeer@gmail.com
ORCID iD: 0009-0004-7290-9122
obstetrician-gynecologist, Chief Physician
Russian Federation, UfaAlsu G. Nazyrova
Anti-aging Medical Clinic GeN
Email: nucleardeer@gmail.com
ORCID iD: 0009-0000-7129-9298
PhD, obstetrician-gynecologist, Deputy General Director for Medical Issues
Russian Federation, UfaReferences
- Marjoribanks J., Farquhar C., Roberts H., Lethaby A., Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 2017; 1(1): CD004143. https://dx.doi.org/10.1002/14651858.CD004143.pub5.
- The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2018; 25(11): 1362-87. https://dx.doi.org/ 10.1097/GME.0000000000001241.
- Chaikittisilpa S., Soimongkol K., Jaisamrarn U. Efficacy of oral estrogen plus testosterone gel to improve sexual function in postmenopausal women. Climacteric. 2019; 22(5): 460-5. https://dx.doi.org/10.1080/13697137.2019. 1577378.
- Morga A., Ajmera M., Gao E., Patterson-Lomba O., Zhao A., Mancuso S. et al. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause. Menopause. 2024; 31(1): 68-76. https://dx.doi.org/10.1097/GME.0000000000002281.
- Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://dx.doi.org/10.3109/ 13697137.2015.1129166.
- Monteleone P., Mascagni G., Giannini A., Genazzani A.R., Simoncini T. Symptoms of menopause - global prevalence, physiology and implications. Nat. Rev. Endocrinol. 2018; 14(4): 199-215. https://dx.doi.org/10.1038/nrendo.2017.180.
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2021. [Ministry of Health of the Russian Federation. Clinical guidelines. Menopause and climacteric state in women. 2021.(in Russian)].
- Kanadys W., Barańska A., Błaszczuk A., Polz-Dacewicz M., Drop B., Kanecki K. et al. Evaluation of clinical meaningfulness of red clover (Trifolium pratense L.) extract to relieve hot flushes and menopausal symptoms in peri- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2021; 13(4): 1258. https://dx.doi.org/10.3390/nu13041258.
- Handley A.P., Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J. Am. Assoc. Nurse Pract. 2015; 27(1): 54-61. https://dx.doi.org/10.1002/ 2327-6924.12137.
- Sarri G., Pedder H., Dias S., Guo Y., Lumsden M.A. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG. 2017; 124(10): 1514-23. https://dx.doi.org/10.1111/1471-0528.14619.
- Castelo-Branco C., Gambacciani M., Cano A., Minkin M.J., Rachoń D., Ruan X. et al. Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence. Climacteric. 2021; 24(2): 109-19. https://dx.doi.org/10.1080/13697137.2020.1820477.
- Рафаэлян И.В., Балан В.Е., Ковалева Л.А. Эффективность и безопасность применения экстракта цимицифуги рацемозы в терапии климактерического синдрома в течение года (результаты собственного исследования). Медицинский совет. 2014; (7): 54-7. [Rafaelyan I., Balan V., Kovaleva L. Efficacy and safety of Cimicifuga racemosa in management of climacteric syndrome during a year (results of own study). Medical Council. 2014; (7): 54-7. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2014-7-54-57.
- Прилепская В.Н., Ледина А.В. Биоактивные компоненты растений и лечение климактерического синдрома. Акушерство и гинекология. 2011; 7-1: 101-8. [Prilepskaya V.N., Ledina A.V. Bioactive components of plants and treatment for menopausal syndrome. Obstetrics and Gynecology. 2011; (7-1): 101-8. (in Russian)].
- Сerqueira R.O., Frey B.N., Leclerc E., Brietzke E. Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch. Womens Ment. Health. 2017; 20(6): 713-9. https://dx.doi.org/ 10.1007/s00737-017-0791-0.
- Verkaik S., Kamperman A.M., van Westrhenen R., Schulte P.F.J. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2017; 217(2): 150-6. https://dx.doi.org/10.1016/j.ajog.2017.02.028.
- Kenda M., Glavač N.K., Nagy M., Sollner Dolenc M., On Behalf Of The Oemonom. Herbal products used in menopause and for gynecological disorders. Molecules. 2021; 26(24): 7421. https://dx.doi.org/10.3390/ molecules26247421.
- Puglia L.T., Lowry J., Tamagno G. Vitex agnus castus effects on hyperprolactinaemia. Front. Endocrinol. (Lausanne). 2023; 14: 1269781. https://dx.doi.org/10.3389/fendo.2023.1269781.
- Seyedabadi S., Hoseini Z.S., Ferns G.A., Bahrami A. Effects of curcumin supplementation on insomnia and daytime sleepiness in young women with premenstrual syndrome and dysmenorrhea: A randomized clinical trial. Avicenna J. Phytomed. 2023; 13(6): 585-96. https://dx.doi.org/10.22038/AJP.2023.21916.
Supplementary files
